Ami Patel, Kyle Rosenke, Elizabeth M Parzych, Friederike Feldmann, Suman Bharti, Amanda J Griffin, Blake Schouest, Matt Lewis, Jihae Choi, Neethu Chokkalingam, Viviane Machado, Brian J Smith, Drew Frase, Ali R Ali, Jamie Lovaglio, Brian Nguyen, Patrick W Hanley, Susanne N Walker, Ebony N Gary, Abhijeet Kulkarni, Allison Generotti, Joseph R Francica, Kim Rosenthal, Daniel W Kulp, Mark T Esser, Trevor R F Smith, Carl Shaia, David B Weiner, Heinz Feldmann
Abstract COVID-19 remains a major public health concern. Monoclonal antibodies have received emergency use authorization (EUA) for pre-exposure prophylaxis against COVID-19 among high-risk groups for treatment of mild to moderate COVID-19. In addition to recombinant biologics, engineered synthetic DNA-encoded antibodies (DMAb) are an important strategy for direct in vivo delivery of protective mAb. A DMAb cocktail was synthetically engineered to encode the immunoglobulin heavy and light chains of two different two different Fc-engineered anti-SARS-CoV-2 antibodies...
January 2, 2024: Emerging Microbes & Infections